Key result
NAE inhibitor MLN4924 effectively suppresses Coxsackievirus B3 replication.
Its licence doesn't allow us to show a copy here.
Why the study?
Despite the high prevalence of Coxsackievirus B infection causing myocarditis and cardiomyopathy, effective antiviral therapy is lacking due to the absence of approved antiviral drugs.
Does the NAE inhibitor MLN4924 suppress Coxsackievirus B3 replication?
Does the NAE inhibitor MLN4924 suppress Coxsackievirus B3 replication?
The NAE inhibitor MLN4924 shows potential as an antiviral therapy by suppressing Coxsackievirus B3 replication, a common cause of viral myocarditis.
Myocarditis, the inflammatory disease of the myocardium, is one of the leading causes of dilated cardiomyopathy and sudden cardiac death. Coxsackievirus B (CVB) is one of the common pathogens of myocarditis and cardiomyopathy. In spite of the high prevalence of CVB infection, effective antiviral therapy is lacking, primarily due to that there is no approved antiviral drug available. In the previous study, we demonstrated that the neddylation of 3D
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied Coxsackievirus B3 infection / Myocarditis. NAE inhibitor MLN4924 was evaluated on Coxsackievirus B3 replication. The NAE inhibitor MLN4924 effectively suppresses Coxsackievirus B3 replication.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: